Alaunos Therapeutics Announces Promising Preclinical Results for ALN1003 in Metabolic Syndrome and Obesity Models
Alaunos Therapeutics Reports Promising Preclinical ALN1003 D...
Sign in to continue:
Alaunos Therapeutics Reports Promising Preclinical ALN1003 D...
EZCORP, Inc. Announces Full Acquisition of Founders One, LLC...
Texas Pacific Land Corporation (TPL) Investor Day Report – M...
InnovAge Holding Corp. Files 8-K, Reaffirms FY2026 Guidance ...
Cognizant Boosts Share Repurchase Target to \$2 Billion in 2...
Boston Omaha Corporation Announces Sale of General Indemnity...
Greenidge Generation Holdings Inc. Reports Q1 2026 Results: ...
CPI Aerostructures Reports Strong Q1 2026 Results: Key Highl...
NextEra Energy and Dominion Energy Announce Transformational...
Turn Therapeutics Appoints Former FDA Commissioner Dr. Steph...